Recent registry data suggest that host-versus-graft alloreactions mediated by anti-donor HLA antibodies in recipients of adult allogeneic hematopoietic stem cells or single-unit umbilical cord blood (UCB) contribute to the risk of graft failure. The present study evaluated the impact of anti-HLA antibodies on engraftment and unit predominance in 126 double-UCB (dUCB) recipients. Eighteen dUCB recipients were identified with at least 1 of 2 UCB units recognized by anti-HLA antibodies directed against donor-directed HLA-specific antibodies (DSAs). Overall, 9 of 12 patients who had DSAs against 1 of the 2 UCB units composing the graft and 5 of 6 patients who had DSAs against both units engrafted. The cumulative incidence of engraftment was similar in patients with and without DSAs (83% vs 78%). Thus, our data do not support a negative effect of anti-HLA antibodies on engraftment, at least in the setting of cyclosporine and mycophenolate mofetil and the conditioning regimens used at the University of Minnesota, and argue against routine screening for use in graft selection before dUCB transplantation. Further studies are needed to fully understand the value of anti-HLA antibody testing in dUCB graft selection and its impact on transplantation outcomes.
INTRODUCTION
The presence of donor-directed HLA-specific antibodies (DSAs) has long been associated with an increased risk of graft failure in solid organ transplantation [1] . Recent reports indicate that graft failure is associated with the presence of DSAs in recipients of related haploidentical [2] and unrelated adult donor hematopoietic cell transplantation (HCT) [3] , as well as single umbilical cord blood (UCB) transplantation [4, 5] . These data suggest that that antibody screening is needed for optimal donor and UCB unit selection.
For more than a decade, the use of 2 partially HLAmatched UCB units, referred to as double UCB (dUCB) transplantation, has helped extend the use of this stem cell source to adults and larger adolescents for whom an adequate single UCB unit is not available. Nonetheless, the rate of neutrophil recovery and hematopoietic engraftment is suboptimal [6, 7] . The median time to neutrophil recovery is 26 days, with a risk of graft failure ranging from 5% to 15% [6, 7] . Reasons for graft failure are likely multifactorial and include the frequent use of grafts that are mismatched at 4 of 6 HLA loci and/or have low but acceptable cell doses. Because the presence of relevant DSAs also may increase the risk of graft failure after UCB transplantation, we evaluated whether DSAs present in the recipient before dUCB transplantation could predict risk of overall engraftment or unit predominance after transplantation.
PATIENTS AND METHODS

Study Design
This retrospective cohort study included dUCB transplant recipients treated at the University of Minnesota Blood and Marrow Transplantation Clinic between 2004 and 2009. Only patients with cryopreserved sera collected before dUCB transplantation and available for anti-HLA antibody analysis were included in the study. The cohort was divided into 2 categories based on exposure to DSAs directed against 1 or both of the donor UCB units. Control subjects were defined as patients exposed to ''irrelevant'' anti-HLA antibodies not directed against either of the UCB units or patients testing negative for all of the anti-HLA antibodies. Demographic and engraftment data were collected prospectively and recorded in the University of Minnesota blood and marrow transplantation database.
For the purpose of this study, donor engraftment was defined as $3 consecutive days with an absolute neutrophil count (ANC) $500/mL in the presence of $5% chimerism. Graft failure was defined as failure to achieve an ANC $500/mL or \5% chimerism by day 142 posttransplantation. Long-term donor predominance was defined as the UCB unit with $70% chimerism at day 1100 or beyond [8] . All patients received treatment with transplantation protocols approved by the University of Minnesota's Institutional Review Board and provided written informed consent according to the principles of the Declaration of Helsinki.
HLA Typing and Antibody Determination
All patients and donors were molecularly HLA typed for HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 at high resolution (allele level). Molecular HLA typing was performed by reverse sequencespecific oligonucleotide probes (LABType SSO; One Lambda, Canoga Park, CA) and by sequencebased typing (AlleleSEQR HLA SBT; Abbott Molecular, Canoga Park, CA). Stored plasma samples were tested retrospectively for the presence of anti-HLA antibody directed against an HLA-A, -B, -C, -DRB1/3/4/5, or -DQB1 antigen on either UCB unit. Because the UCB units were not typed at HLA-DPB1, we were unable to consider that locus. HLA antibody specificities were determined by solid phase, single-antigen bead technology using sequential testing, first with LABScreen Mixed Antigen (One Lambda) and then with single antigen assays if samples were positive with the LABScreen. A positive test for an anti-HLA antibody was defined as an increase in mean fluorescence intensity (MFI) of $500 above the negative control. To verify specificity, each lot of reagents was validated against positive patient samples and standard sera. In addition, in each analytic run, 2 standard sera samples of known specificity and antibody strength from highly sensitized patients were included as positive controls.
Statistical Analysis
Descriptive statistics were analyzed to evaluate patient demographic characteristics and frequency of DSAs. Although we tested for antibodies to high-expression and low-expression loci, we made no distinction between the 2 in the analysis. The cumulative incidence of engraftment was estimated by treating early death (ie, death before day 21 posttransplantation) as a competing risk [9] . The proportional hazards model of Fine and Gray was used to assess the independent effect of anti-HLA antibodies on engraftment, controlling for the CD3 dose (by quartile) and HLA match (match vs mismatch) [10] . All factors were tested for proportional hazards before being included in the regression models. Analyses were performed using SAS 9.2 (SAS Institute, Cary, NC) and R 2.4 (http://cran.r-project.com).
RESULTS
Patient Characteristics and Anti-Donor HLA Alloreactivity
A total of 297 patients received a dUCB transplant between 2004 and 2009. Of these, 126 patients had stored plasma available for retrospective testing for the presence of anti-HLA antibodies. The demographic characteristics of these patients are summarized in Table 1 . Anti-HLA antibodies were present in 50 of the 126 patients (41%) in our study group. Of the 50 patients with one or more anti-HLA antibody, only 12 (24%) had a DSA that targeted 1 UCB unit (Table 2) , and 6 (12%) had a DSA that targeted both UCB units (Table 3) . Among the patients with a DSA (n 5 18), 12 had an antibody directed against a class I antigen, and 8 had an antibody directed against a class II antigen. Only 3 patients had DSAs against both HLA class I and class II antigens, and all 3 of these patients had antibodies targeting both UCB units.
Outcomes of UCB Units Targeted by DSAs
Of the 12 patients with a DSA directed against 1 of 2 UCB units, the targeted unit was detectable at day 121 by chimerism assay in 9 patients, contributing 8%-100% to chimerism (Table 2) . Notably, in 4 patients, the UCB unit targeted by the DSA predominated in the long term as the sole chimeric unit in 3 patients and as 1 of 2 chimeric units (ie, dual chimerism) in 1 patient. In 3 patients, the MFI for the DSA was $3000, with the unit targeted by DSA predominating in 1 patient who engrafted and persisting short-term in 1 patient who engrafted with the nontargeted DSA unit. Graft failure occurred in 2 other patients (one with MFI $3000) in which the unit targeted by the DSA never or only minimally contributed to chimerism. Six patients had DSAs directed against both UCB donor units (Table 3) . In 4 patients, only 1 of the 2 targeted UCB units was detectable by chimerism assay at day 121, whereas in the other 2 patients, both units coexisted at day 121. Alloreactivity against both UCB units was particularly intense (MFI $3000) in 4 patients, only 1 of whom experienced graft failure.
Effect of Anti-Donor HLA Alloreactivity on Hematopoietic Recovery
The cumulative incidence of neutrophil recovery and engraftment for those patients with a DSA UPN indicates unique patient number; NA, not applicable/not available/not achieved. *>500/mL. †Although both unit were detected on chimerism assay beyond day +100, the umbilical cord blood unit with no DSA directed was responsible for >70% of chimerism thus being the predominant one. directed against at least 1 of the 2 UCB units (n 5 18) was 78% (95% confidence interval [CI], 59%-93%), with a median time to recovery of 24.5 days (range, 5-39 days). This incidence of recovery was similar to that in the patients with an irrelevant anti-HLA antibody (n 5 32; 84%; 95% CI, 70%-94%; median, 24 days; range, 3-38 days) and those with no antibody at all (n 5 76; 86%; 95% CI, 85%-94%; median, 19 days; range, 0-42 days; P 5 .54). A multivariate analysis was performed after adjusting for CD3 1 cell dose and HLA matching, factors previously shown to be associated with unit predominance after dUCB transplantation [8] . Compared with the patients with DSA (n 5 107), no effect could be discerned for the presence of DSA on engraftment (relative risk [RR], 0.68; 95% CI, 0.36-1.29; P 5 .24).
DISCUSSION
In the present study, the cumulative incidence of engraftment seems to be unaffected by the presence of DSAs in patients undergoing HCT with 2 partially HLA-matched UCB units. Unlike previous reports in the context of adult unrelated donor allogeneic HCT [3] and single-unit UCB transplantation [4] , the presence of DSAs targeting 1 or both UCB donor units failed to impair engraftment and had no effect on which unit predominated over the long term. Takanashi et al. [4] found an incidence of neutrophil recovery of only 32% in 20 patients with a DSA directed against the UCB donor unit. Similar results were reported by Spellman et al. [3] in the context of adult unrelated donor allogeneic HCT, with donor graft failure occurring in 9 of 10 patients with a DSA, and by Ciurea et al. [2] in the context of haploidentical transplantation, with graft failure occurring in 3 of 4 patients with a DSA. In contrast, the majority of the 18 patients (78%) in our study achieved long-term engraftment despite testing positive for a DSA against 1 or both UCB units. Although it can be speculated that our patients were protected from graft failure by the presence of 2 UCB units, this may be the only reason for the differences in outcome, given that engraftment was observed in 5 of 6 patients (83%) with antibodies directed against both units. However, in the first 12 patients, 7 of 10 evaluable patients (excluding 1 patient with early death and 1 patient with autologous recovery) demonstrated engraftment with the unit against which there was no DSA. Thus, even though immediate rejection of units against which there is a DSA does not occur, DSA is possibly associated with failure to engraft long term, favoring engraftment of the unit against which there is no DSA.
One limitation of the present study is the absence of analysis for DSA against HLA-DPB1. It remains possible that antibodies directed against -DP or other antigens on UCB influence graft failure or unit predominance. Taken together, our data suggest that donor-specific HLA alloresponses might not increase the risk of graft failure in dUCB transplantation. Whether or not DSA influences unit predominance after dUCB transplantation remains to be determined in larger number of patients.
Although screening for DSAs is certainly feasible [11] , it might add to healthcare costs, delay donor acquisition, and lead to the selection of a donor unit with a lower cell dose or greater HLA mismatch, all of which are factors proven to negatively impact survival. We recognize that our small sample size might have prevented us from detecting the impact of anti-HLA antibodies, and that different conditioning regimens and posttransplantation immunosuppressive therapies might have altered our results; nevertheless, we cannot recommend routine anti-HLA antibody screening for UCB unit selection in the setting of dUCB transplantation, because this practice could result in the selection of less suitable units. Additional data in larger numbers of patients are needed to establish a clear association between DSA and graft failure or unit loss in the setting of dUCB transplantation.
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